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A B S T R A C T
Purpose
Diffuse intrinsic pontine glioma (DIPG) is a brainstemmalignancy with a median survival of, 1 year.
The International and European Society for Pediatric Oncology DIPG Registries collaborated to
compare clinical, radiologic, and histomolecular characteristics between short-term survivors (STSs)
and long-term survivors (LTSs).
Materials and Methods
Data abstracted from registry databases included patients from North America, Australia, Germany,
Austria, Switzerland, the Netherlands, Italy, France, the United Kingdom, and Croatia.
Results
Among 1,130 pediatric and young adults with radiographically confirmed DIPG, 122 (11%) were
excluded. Of the 1,008 remaining patients, 101 (10%) were LTSs (survival$ 2 years). Median survival
time was 11 months (interquartile range, 7.5 to 16 months), and 1-, 2-, 3-, 4-, and 5-year survival rates
were 42.3% (95%CI, 38.1% to 44.1%), 9.6% (95%CI, 7.8% to 11.3%), 4.3% (95%CI, 3.2% to 5.8%),
3.2% (95% CI, 2.4% to 4.6%), and 2.2% (95% CI, 1.4% to 3.4%), respectively. LTSs, compared with
STSs, more commonly presented at age, 3 or. 10 years (11% v 3% and 33% v 23%, respectively;
P, .001) and with longer symptom duration (P, .001). STSs, compared with LTSs, more commonly
presentedwith cranial nerve palsy (83% v 73%, respectively;P= .008), ring enhancement (38% v 23%,
respectively;P= .007), necrosis (42% v 26%, respectively;P= .009), and extrapontine extension (92% v
86%, respectively; P = .04). LTSs more commonly received systemic therapy at diagnosis (88% v
75% for STSs; P = .005). Biopsies and autopsies were performed in 299 patients (30%) and 77
patients (10%), respectively; 181 tumors (48%) were molecularly characterized. LTSs were more
likely to harbor a HIST1H3B mutation (odds ratio, 1.28; 95% CI, 1.1 to 1.5; P = .002).
Conclusion
We report clinical, radiologic, and molecular factors that correlate with survival in children and young
adults with DIPG, which are important for risk stratification in future clinical trials.
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INTRODUCTION
Diffuse intrinsic pontine glioma (DIPG) is a malignant brainstem
tumor of childhood for which median survival is , 1 year.1 Long-
term survival, historically defined as overall survival (OS) . 2
years, is reported in , 10% of patients.1 Characteristics associated
with longer survival include younger age, longer symptom latency,
and absent ring enhancement on diagnostic magnetic resonance
imaging.1,2 Up to 90% of DIPGs harbor a pathognomonic point
mutation inH3F3A (65% of tumors) orHIST1H3B (25% of tumors);
the latter seems to confer longer survival. Ten percent of patients
have a histone 3 wild-type tumor.3
Involved-field radiation therapy (RT) remains standard of care
but confers only a 3- to 4-month survival advantage. Benefit from
neoadjuvant4 or adjuvant2,5 chemotherapy has not been consistently
confirmed in prospective trials.
The rarity and inconsistent classification of DIPG, an imaging-
based diagnosis, have long hampered cross-cohort comparisons. The
primary aim of this multinational collaboration between the In-
ternational DIPG Registry (IDIPGR) and European Society for
Pediatric Oncology DIPG Registry (SIOPE-DIPGR)6,7 was to define
clinical, radiologic, histologic, and molecular factors associated with
short- and long-term survival in the largest cohort of centrally
reviewed DIPGs to date.
MATERIALS AND METHODS
Study Population
The study was approved by the institutional review board at Cin-
cinnati Children’s Hospital Medical Center and included 1,130 patients
with radiographically confirmed DIPG diagnosed from 1990 to 2015.
IDIPGR patients (n = 409) were age 0 to 27 years from the United States,
Canada, and Australia. SIOPE-DIPGR patients (n = 721) were age 0 to 21
years from the Netherlands, Germany, Austria, Switzerland, Italy, France,
the United Kingdom, and Croatia. Patients were referred to the registries as
previously described.6,7 Exclusion criteria are listed in Figure 1. No patients
with neurofibromatosis type 1 were included.
Clinical Variables
Clinical data were abstracted (J.B., B.C., S.E.M.V.v.Z., and N.C.) using
standardized case report forms. Cerebellar signs included dysmetria,
ataxia, dysarthria, or nystagmus. Pyramidal tract signs included mono-,
hemi-, or quadriparesis; hyperreflexia; or positive Babinski sign. Because
over survival (OS), defined as the time from diagnosis to death or last
follow-up, is regarded as the most reliable outcome variable for DIPG,
progression-free survival (PFS) was not reported. Short-term survivors
(STSs), long-term survivors (LTSs), and very long–term survivors (VLTSs)
had OS times of , 24, $ 24, and $ 60 months, respectively. Two LTSs
(patients DIPG-0016 and DIPG-0081) lost to follow-up at our data cutoff
(January 1, 2017) were included in primary statistical analyses.
Radiologic Variables
Anonymized diagnostic magnetic resonance imaging was centrally
reviewed (M.W., B.B., E.S., R.C., J.L., and B.J.) and classified as typical or
unlikely DIPG; the latter were excluded. Typical DIPGs arose from and
diffusely involved $ 50% of the pons. Exclusionary features included
focally exophytic morphology, marked diffusion restriction, or second-
ary brainstem involvement by a tumor centered elsewhere in the brain or spine.
Diagnostic imaging from all LTSs and 10% of STSs was cross-validated by
a neuroradiologist from the other registry. Metastatic disease, defined as
noncontiguous tumor in the brain or spine, was reported by individual
sites but not centrally reviewed.
Histopathologic and Molecular Variables
Histology was defined according to 2007 WHO criteria8; based on
availability of tissue in the registries, 61 tumor specimens were centrally
reviewed (C.F. and C.H.). Databases were queried for common genomic
alterations in DIPG. Histone mutations were assessed by Sanger sequencing,
whole-exome sequencing, or whole-genome sequencing, polymerase chain
reaction, or immunohistochemistry to detect H3K27M-mutant protein or
H3K27 trimethylation (H3K27me3). Mutations inH3F3A (H3.3 K27M) or
HIST1H3B (H3.1 K27M) were considered mutually exclusive even if both
were not evaluated.
Statistical Analyses
Patient characteristics were summarized using medians and ranges or
frequencies and percentages. Univariable analyses were performed using
the Fisher’s exact test or Wilcoxon rank sum test. Multivariable logistic
regression was performed on variables with , 15% missing data and
univariable P , .1; however, transverse tumor dimension was excluded as
a result of high correlation with craniocaudal dimension. For subgroup
analyses, multivariable logistic regression models were used to determine
subgroup significance and adjusted for confounding factors. Survival was
estimated using the Kaplan-Meier method. Statistical evaluation was per-
formed using R (Version 3.1.3). P , .05 was considered significant.
RESULTS
Survival
A total of 1,008 patients met inclusion criteria (IDIPGR, n =
374; SIOPE-DIPGR, n = 634). Median survival time was 11months
Radiographically-confirmed DIPGs
 (N = 1,130)
Patients with DIPGs included
 (n = 1,008)
Diagnosed < 2 years from data cutoff
(n = 27)
Survival status unknown
(n = 39)
Treatment unknown
(n = 5)
No intent to treat at diagnosis
(n = 38)
Less than 50% pontine involvement
(n = 5)
WHO grade 1 glioma
(n = 3)
Nonglioma histology
(n = 5)
Fig 1. Flowchart of patients excluded from this study. DIPG, diffuse intrinsic
pontine glioma.
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(interquartile range, 7.5 to 16 months), and 1-, 2-, 3-, 4-, and 5-year
OS rates were 42.3% (95% CI, 38.1% to 44.1%), 9.6% (95% CI,
7.8% to 11.3%), 4.3% (95% CI, 3.2% to 5.8%), 3.2% (95% CI,
2.4% to 4.6%), and 2.2% (95% CI, 1.4% to 3.4%), respectively.
Characteristics of 101 LTSs (10%) and 16 VLTSs (1.6%) are shown
in Figure 2 and Appendix Figure A1 (online only), respectively. Kaplan-
Meier survival analyses for age, symptom duration, systemic therapy,
histology, and molecular status are shown in Figure 3.
Clinical Presentation
Median age was 6.8 years (range, 0 to 26.8 years); 4% of patients
were age , 3 years at diagnosis. Of patients with available data, 755
(82%) of 917, 468 (51%) of 915, and 567 (62%) of 920 patients
presented with one or more cranial nerve (CN) palsy, pyramidal
tract, or cerebellar sign, respectively. On univariable analysis (Table 1),
LTSs were more likely to be age , 3 years (28% v 3% of STSs) or
. 10 years (33% v 23% of STSs; P, .001) and had longer symptom
duration at diagnosis. LTSs were less likely to present with CN palsy
(72% v 83% of STSs; P = .008). Multivariable analyses (Table 2)
confirmed association of age and symptom duration with long-term
survival but failed to associate CN palsy with short-term survival.
Therapy
Thirty-eight patients (3%) who did not receive therapy at
diagnosis (Appendix Fig A2A, online only) were excluded. Un-
treated patients were more often, 3 years old at diagnosis. Eleven
patients underwent biopsy or autopsy. At progression, one patient
received chemotherapy; no patients received RT. Median OS of
untreated patients was 1month (range, 0 to 135months). Two patients
were LTSs (both infants), including one who was alive 135 months
after diagnosis (Appendix Fig A2B, online only).
The status of RT and systemic therapy was known for 968
patients; 721 patients (74%) received both RT and systemic therapy,
231 patients (24%) received RTalone, and 16 patients (2%) received
systemic therapy alone. In univariable and multivariable analyses,
LTSs more commonly received systemic therapy at diagnosis (88% v
75% for STSs; P = .005; odds ratio [OR], 3; 95% CI, 1.46 to 7.3;
P = .01). Systemic therapy type was known for 702 patients (70%);
350 patients (50%) received cytotoxic therapy only, 193 patients
(27%) received targeted therapy only, and 159 patients (23%)
received both cytotoxic and targeted. On univariable analysis, type
of targeted therapy yielded no survival difference (Table 1).
However, multivariable logistic regression adjusted for age and
symptomdurationdemonstrated greater odds of long-term survivalwith
use of an epidermal growth factor receptor (EGFR) inhibitor (OR, 2.32;
95%CI, 1.1 to 4.82; P= .03) or bevacizumab (OR, 2.67; 95%CI, 1.09 to
6.55; P = .03), an anti–vascular endothelial growth factor (VEGF) an-
tibody, at diagnosis (Table 2). Seventy-two patients (7%) underwent
reirradiation at first or subsequent progression (as reported by individual
sites). The rate offirst progression recordedwithin 1 year of diagnosiswas
significantly lower in patients who underwent reirradiation compared
with patients who did not (74% v 88%, respectively; P = .007).
Imaging
Table 1 lists diagnostic imaging characteristics. STSs dem-
onstrated larger craniocaudal tumor dimension (43 v 40 mm for
LTSs; P = .04) and higher rates of extrapontine extension (92% v
85% for LTSs; P= .04), tumor necrosis (45% v 26% for LTSs;P= .009),
and ring enhancement (38% v 23% for LTSs; P = .007). Metastatic
disease at diagnosis was reported in 18 STSs (2%) and no LTSs.
Histology and Molecular Characteristics
More SIOPE-DIPGR patients (39%) than IDIPGR patients
(14%) underwent biopsy, and more IDIPGR patients (16%) than
SIOPE-DIPGR patients (4%) underwent autopsy (Appendix Table
A1, online only). LTSs from both registries were more often
biopsied than STSs (38% v 28%, respectively; P = .04). Histology
and WHO grade were known for 288 biopsy and 76 autopsy
samples. WHO grade did not influence survival. Biopsy specimens
included glioblastoma multiforme (GBM; n = 80), anaplastic
astrocytoma (n = 76), anaplastic oligodendroglioma (n = 10),
diffuse astrocytoma (n = 37), fibrillary astrocytoma (n = 4), oligo-
dendroglioma (n = 2), low-grade astrocytoma (n = 8), and unknown
(n = 71). Histology of autopsy tissue included GBM (n = 48),
anaplastic astrocytoma (n = 12), diffuse astrocytoma (n = 3), and
unknown (n = 13).
Of 376 patients fromwhom tissue was obtained, genomic data
were available for 181 (48%) of patients (18% of the entire cohort;
Data Supplement), including 21 LTSs (Fig 4). Global molecular
assessment was undertaken for 44 patients (whole-genome se-
quencing, n = 16; whole-exome sequencing, n = 25; 450k
methylation array, n = 3), whereas 98 patients underwent limited
genomic sequencing (Sanger, n = 80; other targeted platform,
n = 18), and 36 patients underwent immunohistochemistry alone.
H3.1 K27M was associated with longer median OS (15 months)
and long-term survival in multivariable analysis (OR, 1.28; 95%
CI, 1.1 to 1.5; P = .002). In contrast, H3.3 K27M was associated
with short-term survival (OR, 0.88; 95% CI, 0.78 to 0.99; P = .04;
median survival, 10.4 months). Patients with H3 wild-type tumors
(n = 26) had a median OS of 10.5 months. WHO grade did not
correlate with histone mutation status. TP53 and ACVR1 muta-
tions were not associated with survival. Of the 50 patients age. 10
years at diagnosis, who as a group demonstrated higher likelihood
of long-term survival, 38 (78%) harbored H3.3 K27M, nine (18%)
were H3 wild-type, and only three (6%) had H3.1 K27M.
DISCUSSION
This study confirms the relevance of some previously reported
survival-associated factors in patients with DIPG and offers unique
insight into 101 LTSs (including 16 VLTSs). Median survival for all
1,008 patients was 11 months.1,5 Median survival times of LTSs and
VLTSs were 33 months (range, 24 to 156 months) and 78 months
(range, 60 to 156 months), respectively. Of 16 surviving patients,
two were lost to follow-up but were LTSs at the time of last contact
(patients DIPG-0016 and DIPG-0081; OS, 33 and 36 months). The
2-year OS rate of 9.6% in this study was consistent with large
retrospective studies2,5 that reported 9.2% and 9% 2-year OS rates
in 153 and 316 patients with DIPG, respectively. The 1-year OS rate
in our study (42.3%) is comparable to that reported by Hassan
et al9 in a meta-analysis of 2,336 pediatric patients with high-grade
brainstem glioma (41%); however, the 2- and 3-year OS rates of
15.3% (95% CI, 12% to 20%) and 7.3% (95% CI, 5.2% to 10%) in
jco.org © 2018 by American Society of Clinical Oncology 1965
Long-Term Survivors of Diffuse Intrinsic Pontine Glioma
P
at
ie
n
t
A
g
e 
(m
o
n
th
s)
S
ex
C
N
 P
al
sy
C
er
eb
el
la
r
P
yr
am
id
al
 
S
ym
p
to
m
 D
u
ra
ti
o
n
 
(w
ee
ks
)
S
ys
te
m
ic
 T
h
er
ap
y
R
T
R
e-
R
T
S
ys
te
m
ic
 T
h
er
ap
y 
T
yp
e
T
is
su
e
W
H
O
 G
ra
d
e
H
3 
S
ta
tu
s
S
ta
tu
s 
at
 L
FU
O
S  
(m
o
n
th
s)
DIPG 149 73 No No Yes < 6 Yes Yes No Other 24
DIPG 164 50 Yes Yes No Other 24
DIPG 336 189 Yes No Yes 6-12 Yes Yes No 24
DIPG 354 125 Yes No Yes < 6 Yes Yes No 24
FR 299 94 Yes Yes No < 6 No Yes No H3.3 24
GER 368 81 No No < 6 Yes Yes No HDAC 4
4
4
4
4
4
4
24
GER 399 188 Yes No No 12-24  Yes Yes No 24
GOSH 30 49 Yes No Yes < 6 Yes Yes No 24
NETH 162 204 Yes Yes Yes 6-12
6-12
6-12
6-12
6-12
6-12
6-12
6-12
6-12
Yes Yes No EGFR H3.3 24
DIPG 215 71 Yes Yes No Unkn 24
DIPG 155 145 No No No Yes Yes No 2 24
DIPG 22 93 No No Yes < 6 Yes Yes No Bev H3.1 24
DIPG 83 97 Yes No Yes < 6 Yes Yes No Other 25
DIPG 160 54 Yes Yes Yes Yes No Unkn 25
FR 333 70 No Yes No < 6 Yes Yes Yes EGFR H3.1 25
GER 370 93 Yes No Yes < 6 Yes Yes No HDAC 25
IT 19 44 Yes Yes No < 6 Yes Yes Yes EGFR 25
IT 79 241 Yes Yes Yes Yes Yes Yes EGFR 25
NETH 111 97 No No Yes < 6 No Yes No 25
DIPG 40 78 < 6 Yes Yes No EGFR 25
DIPG 371 77 Yes No No < 6 Yes Yes No Other 26
FR 250 93 Yes Yes Yes < 6 Yes Yes No EGFR 26
FR 258 75 No No Yes < 6 Yes Yes No EGFR H3 26
FR 270 91 Yes No Yes No Yes No 26
FR 337 39 Yes Yes Yes Yes Yes No EGFR 3
3
3
H3.1 26
GER 383 42 Yes Yes No < 6 Yes Yes No HDAC 26
DIPG 247 188 No Yes Yes Yes No 26
FR 350 79 Yes No Yes Yes Yes Yes mTOR 2
2
2
H3.3 27
GER 372 77 < 6 Yes Yes No 27
DIPG 35 145 Yes No Yes < 6 Yes Yes No Bev 27
DIPG 96 78 Yes No Yes Yes Yes 28
DIPG 526 98 Yes Yes No Yes Yes No Bev H3.3 28
FR 366 170 Yes No Yes Yes Yes Yes EGFR WT 28
GER 375 142 No No No > 24 Yes Yes No WT 28
GER 390 59 No Yes Yes < 6 Yes Yes No 28
IT 10 64 Yes No Yes Yes Yes No 28
GER 393 138 Yes No No Yes Yes No 29
IT 11 48 Yes Yes Yes < 6 Yes Yes No 29
GER 369 106 Yes Yes < 6 Yes Yes No HDAC 30
GER 376 136 No No Yes < 6 Yes Yes No HDAC 30
GER 401 54 Yes No Yes < 6 Yes Yes No 30
IT 20 207 Yes No No < 6 Yes Yes Yes EGFR 30
IT 81 104 Yes No No 12-24  Yes Yes Yes EGFR 30
NETH 141 183 Yes Yes Yes 12-24  Yes Yes No 30
DIPG 157 56 Yes Yes Yes 12-24  Yes Yes No EGFR 31
DIPG 79 33 Yes Yes No 32
GER 373 78 Yes Yes Yes < 6 No Yes No 32
NETH 160 147 Yes Yes Yes < 6 No Yes No 32
DIPG 107 54 Yes Yes No 2 32
DIPG 31 34 No No No 12-24  Yes No 4 H3.3 32
DIPG 486 92 Yes No Yes Yes Yes Yes mTOR 33
GER 388 214 No Yes No 12-24  Yes Yes No 4 H3.3 33
DIPG 114 27 6-12  Yes Yes No 33
DIPG 16 264 No No Yes 6-12  Yes Yes No Bev 2 34
CRO 6 49 Yes Yes No 12-24  Yes Yes No 34
FR 332 89 Yes Yes No < 6 Yes Yes No EGFR 4 H3.1 34
GER 371 97 Yes No No < 6 Yes Yes No 34
DIPG 119 69 Yes No Yes < 6 Yes Yes No 4 H3.1 35
GER 114 91 Yes No No < 6 Yes Yes No 35
IT 17 202 Yes Yes Yes > 24 Yes Yes Yes EGFR 35
IT 13 86 Yes Yes No 6-12  Yes Yes No EGFR
DIPG 81 321 No No No 6-12 Yes Yes No EGFR 2
CRO 7 135 Yes Yes No < 6 Yes Yes No 3
GER 379 39 No No No < 6 Yes Yes No
DIPG 332 198 Yes Yes Yes 6-12  Yes Yes No Other
FR 365 26 Yes Yes No No Yes Yes H3.3
IT 18 70 Yes Yes No < 6 Yes Yes No EGFR
NETH 184 109 No Yes Yes 12-24  No Yes No 4 H3.1
GER 374 41 Yes No Yes < 6 Yes Yes No
GER 398 158 Yes Yes No > 24 Yes Yes Yes 3 H3.1
DIPG 452 60 < 6 Yes Yes Yes Unkn
GER 378 57 No Yes No < 6 Yes Yes No 2
NETH 133 46 Yes Yes Yes > 24 No Yes No 4
DIPG 68 158 No No No 6-12  Yes Yes No Bev
GER 274 48 No Yes Yes > 24 Yes No No 2 H3.3
GER 400 127 Yes No No 12-24  Yes Yes No HDAC 2
GOSH 12 42 Yes No Yes > 24 Yes Yes No
DIPG 251 80 No No Yes No Yes No 3 H3.3
FR 302 24 Yes No No Yes Yes No EGFR 3 H3.3
DIPG 193 51 < 6 Yes No
GER 392 42 Yes Yes No > 24 Yes Yes No
NETH 112 27 Yes No No 6-12  No Yes No 2
NETH 98 50 Yes Yes Yes > 24 No Yes No
DIPG 46 70 < 6 Yes Yes No
GER 385 149 No No No > 24 Yes Yes No
GOSH 14 108 Yes No No < 6 Yes Yes Yes
GER 380 161 Yes No No > 24 Yes Yes No
GER 386 23 Yes No Yes 6-12  Yes No No
IT 15 33 Yes Yes No 12-24  Yes Yes No EGFR
DIPG 449 169 > 24 Yes Yes No Other
GER 387 169 No No No 6-12  Yes Yes Yes
NETH 120 134 No Yes Yes < 6 No Yes No
NETH 194 26 No Yes Yes > 24 Yes Yes No
DIPG 641 288 Yes No No < 6 Yes Yes Yes Bev 2 H3.3
GER 391 123 Yes No Yes < 6 Yes Yes No
IT 14 101 Yes No No 12-24  Yes Yes No EGFR
GER 397 23 Yes Yes No < 6 Yes Yes Yes
GER 377 174 Yes No No > 24 Yes Yes No HDAC
DIPG 528 33 < 6 Yes Yes No Other
UK 9 185 Yes Yes No > 24 Yes Yes No EGFR 2
IT 12 83 Yes No Yes < 6 Yes Yes No
No Treatent at Diagnosis
GER 382 37 Yes No No < 6 No No No
NETH 164 28 Yes Yes Yes > 24 No No No
81
58
59
60
67
70
70
56
135
86
89
99
101
102
156
72
75
75
77
78
56
46
46
49
49
50
50
52
52
52
53
54
46
36
36
38
39
39
40
40
41
42
45
Age
< 3 years
3-10 years
> 10 years
Sex
Female
Male
Yes
No
< 6 weeks
6-12 weeks
12-24 weeks
> 24 weeks
Yes
No
Cytotoxic
Targeted
Both
Tissue
Biopsy
Autopsy
Both
WHO Grade
2
3
4
H3.3
H3.1
Wild-type
Survival
≥ 2 years
≥ 3 years
≥ 4 years
≥ 5 years
RT, Systemic Therapy, 
Re-RT
CN, Cerebellar, 
Pyramidal
Symptom Duration
Systemic Therapy Type
Histone Status
Status at LFU
Alive
Deceased
Fig 2. Clinical, histologic, and molecular character-
istics of long-term survivors of diffuse intrinsic pontine
glioma. Bev, bevacizumab; CN, cranial nerve; CRO,
Croatia; DIPG, International DIPG Registry; EGFR,
epidermal growth factor receptor; FR, France; GER,
Germany, Switzerland, Austria; GOSH, Great Ormond
Street Hospital; HDAC, histone deacetylase inhibitor;
IT, Italy; LFU, last follow-up; mTOR, mammalian target
of rapamycin inhibitor; NETH, the Netherlands; OS,
overall survival; Re-RT, reirradiation; RT, radiation therapy;
UK, United Kingdom; Unkn, unknown.
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Fig 3. Kaplan-Meier curves representing overall survival (OS) based on (A) patient age (years), (B) symptom duration (weeks), (C) systemic therapy at diagnosis, (D)WHO
grade, or (E) histone status. WT, wild type.
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their study were higher than those in our study (9.6% and 4.3%,
respectively), likely reflecting the heterogeneity of their cohort,
some whom may not have true DIPGs.
Previously, 43 VLTSs had been reported in the literature.1,10-15
In Appendix Figure A1, we compare the characteristics of 22
previously published VLTSs to our 16 VLTSs, including eight
(0.02% of the total cohort) who are alive with a median follow-up
time of 6.5 years (range, 5 to 13 years). Our 5-year OS rate of 2.3%
is comparable to the rate of 2.6% reported by Jackson et al1 in 191
patients with DIPG; however, two of their five VLTSs would have
been excluded from our study for atypical magnetic resonance
imaging features. Freeman et al12 reported nine VLTSs (6.9%)
among 130 patients with DIPG treated with hyperfractionated
RT (Pediatric Oncology Group 8495 trial), although only four of
these patients (3%) would have met inclusion criteria in our
study.
Age , 3 or . 10 years, longer symptom latency, lack of CN
palsy, and systemic therapy at diagnosis were predictors of long-
term survival. Of 41 patients age, 3 years at diagnosis, 36 received
first-line RT with or without systemic therapy and five received
systemic therapy alone. Although median OS for children age , 3
years (11 months) was the same as the entire cohort, a greater
proportion was LTSs or VLTSs. Other studies have reported similar
findings.1,2,5,16 Broniscer et al17 described 10 DIPG patients age
, 3 years who received RTwith or without chemotherapy (n = 8)
or chemotherapy only (n= 2) at diagnosis (n= 6) or progression (n= 4).
Five patients (50%) were LTSs, including one treated without RT.
Wagner et al5 similarly reported higher median survival in 13
Table 1. Results of Univariable Analyses Comparing Clinical, Radiologic, and
Histologic Characteristics of Long- and Short-Term Survivors of Diffuse
Intrinsic Pontine Glioma
Characteristic LTSs (n = 101) STSs (n = 907) P
Clinical
Registry, No. (%) .39
International 33 (9) 341 (91)
SIOPE 68 (11) 566 (89)
Sex, No. (%) .46
Male 51 (50) 420 (46)
Female 50 (50) 485 (54)
Race, No. (%) .43
African 4 (9) 43 (12)
Asian 2 (4) 14 (4)
White 36 (80) 237 (69)
Other 3 (7) 50 (15)
Median age, years (range) 7.2 (1.9-26.8) 6.8 (0-26.5) .61
Age, years, No. (%) , .001
, 3 11 (11) 29 (3)
3-10 57 (56) 668 (74)
. 10 33 (33) 205(23)
Symptom duration, weeks, No. (%) , .001
, 6 45 (51) 564 (69)
6-12 19 (21) 156 (19)
12-24 11 (12) 62 (8)
. 24 14 (16) 35 (4)
Symptoms at diagnosis, No. (%)
Cranial nerve palsy .008
Yes 63 (73) 692 (83)
No 25 (27) 137 (17)
Pyramidal tract sign .5
Yes 39 (44) 429 (52)
No 50 (56) 397 (48)
Cerebellar sign .08
Yes 46 (53) 521 (63)
No 41 (47) 312 (37)
CSF diversion, No. (%) 1.00
Yes 22 (22) 196 (22)
No 79 (78) 709 (78)
Systemic therapy at diagnosis, No. (%) .005
Yes 85 (88) 644 (75)
No 12 (12) 214 (25)
Category of systemic therapy, No. (%) .07
Cytotoxic chemotherapy 36 (44) 314 (51)
Targeted chemotherapy 19 (23) 174 (28)
Both 27 (33) 132 (21)
Chemotherapy type, No. (%)
Cytotoxic 63 (56) 446 (60) .43
EGFR inhibitor 21 (19) 114 (15) .14
HDAC inhibitor 8 (7) 54 (7) .68
mTOR inhibitor 2 (2) 14 (2) 1.00
Bevacizumab 8 (7) 44 (6) .37
Other targeted agent 10 (9) 88 (12) .74
Radiologic
Median tumor size, mm (range)
AP 36 (18-57) 36 (14-70) .98
Transverse 43 (15-76) 45 (17-81) .08
CC 40 (20-88) 43 (16-107) .04
Median pons size, mm (range)
AP 36 (21-50) 35 (20-58) .12
Transverse 49 (31-62) 48 (22-78) .62
Extrapontine extension, No. (%) .04
Yes 78 (86) 739 (92)
No 13 (14) 60 (8)
(continued in next column)
Table 1. Results of Univariable Analyses Comparing Clinical, Radiologic, and
Histologic Characteristics of Long- and Short-Term Survivors of Diffuse
Intrinsic Pontine Glioma (continued)
Hemorrhage, No. (%) .35
Yes 11 (14) 136 (19)
No 68 (86) 588 (81)
Necrosis, No. (%) .009
Yes 20 (26) 306 (42)
No 56 (74) 424 (58)
Hydrocephalus, No. (%) 1.00
Yes 14 (18) 136 (18)
No 65 (82) 632 (82)
Tumor margin, No. (%) .14
Ill defined 64 (75) 605 (82)
Well defined 21 (25) 132 (18)
Ring enhancement, No. (%) .007
Yes 19 (23) 281 (38)
No 63 (77) 457 (62)
Histologic
Biopsy, No. (%) .03
Yes 38 (38) 249 (28)
No 61 (62) 652 (72)
Autopsy, No. (%) .04
Yes 11 (18) 65 (10)
No 49 (82) 597 (90)
WHO grade, No. (%) .08
2 12 (41) 40 (21)
3 9 (31) 76 (40)
4 8 (28) 73 (39)
Abbreviations: AP, anterior-posterior; CC, craniocaudal; EGFR, epidermal growth
factor receptor; HDAC, histone deacetylase; LTSs, long-term survivors; mTOR,
mammalian target of rapamycin; SIOPE, European Society for Pediatric Oncol-
ogy; STSs, short-term survivors.
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children with DIPG age , 4 years compared with older children
(13.6 v 10 months); only eight patients (61%) received RT. Although
limitations to our data precluded making conclusions about biologic
differences in this young age group, we postulate that unique mech-
anisms, such as potently oncogenicNTRK fusions described in infantile
midline high-grade gliomas,18 may underlie this observed survival
advantage.
Patients age . 10 years at diagnosis had longer median OS
(13months) and weremore likely to be LTSs. Bailey et al19 similarly
reported five LTSs (all . 9 years old) among 43 patients with
radiographically confirmed DIPG. In contrast, Veldhuijzen van
Zanten et al16 reported no difference in OS between patients age
9 to 18 years versus younger patients. Although pathogenic
mechanisms, such as low-grade histology or IDH mutation may
influence survival in older patients, 78% of patients. 10 years old
in our study harbored the poor prognostic H3.3 K27M mutation.
Clinical and molecular characteristics for patients age . 18 years
(n = 13) were also similar to their younger counterparts (Appendix
Fig A3, online only).
Consistent with prior reports,1,2 the presence of symptoms
for . 24 weeks at diagnosis was strongly associated with longer
survival in univariable and multivariable analyses. CN palsy at
diagnosis predicted shorter survival in univariable but not mul-
tivariable analysis. Previous studies reporting association of CN
palsy with shorter survival included all brainstem tumors, not just
DIPG, and/or diagnosis based on computed tomography scan,
making comparison difficult.20
Neoadjuvant or adjuvant systemic therapy correlated with
long-term survival in both univariable and multivariable analyses.
This finding differs from the long-standing view that systemic
therapy provides no survival benefit for DIPG, a principle largely
based on small, nonrandomized clinical trials. Effective cross-
comparison of therapeutic studies for DIPG has been hindered
by wide variation in inclusion criteria, as demonstrated in studies
by Hargrave et al21 and Jansen et al22 in which only six of 29 DIPG-
specific therapeutic trials between 1984 and 2012 had comparable
eligibility. In a randomized trial, Wagner et al5 reported better
median OS in patients with DIPG treated with adjuvant chemo-
therapy after RT (11.3 months) compared with patients treated
with RT alone (9.5 months; P = .03). Similarly, others have re-
ported superior median OS with use of adjuvant or neoadjuvant
chemotherapy.4
Multivariable logistic regression demonstrated higher odds of
long-term survival with use of EGFR inhibitors (eg, gefitinib, erlotinib,
nimotuzumab, rindopepimut, cetuximab) or bevacizumab at di-
agnosis. A phase II study of gefitinib with RT in newly diagnosed
patients with DIPG noted 2-year OS of 19.6%with PFS. 36months
in three patients.23 In a biopsy-mandated phase I study of erlotinib with
RT, EGFR overexpression trended toward longer PFS (10.1 months
v 6.3 months in patients without EGFR overexpression; P = .058)
but not OS.24 Despite only modest activity of nimotuzumab in
progressive DIPG, two patients lived for 663 and 481 days from the
start of therapy.25
Despite efficacy in adult GBM, bevacizumab has shown little
activity in pediatric trials for newly diagnosed26 or progressive
DIPG27 (median PFS, 2.3 months). However, in a phase I trial of
vandetanib, a selective vascular endothelial growth factor receptor
receptor 2 (VEGFR2) and EGFR inhibitor, in newly diagnosed
DIPG, Broniscer et al28 reported 2-year OS of 21.4%, and higher
levels of plasma VEGF were associated with longer PFS (P = .02).
Although numbers were too small to assess patient outcomes based
on genomically matched targeted therapy, our findings support
prospective assessment of biopsy tissue to define potential therapeutic
targets, as recently undertaken in two multi-institution, multinational
trials (ClinicalTrials.gov identifiers: NCT01182350 andNCT02233049).
Table 2. Results of Multivariable Cox Proportional Analysis of Clinical,
Radiologic, and Molecular Variables Predicting Survival
Variable Odds Ratio (95% CI) P
Clinical
Age, years .02
, 3 2.82 (1.06 to 10.28)
3-10 1.0
. 10 2.24 (1.27 to 3.96)
Symptom duration, weeks , .001
, 6 1.0
6-12 1.49 (0.76 to 2.92)
12-24 2.43 (1.04 to 5.75)
. 24 5.7 (2.77 to 14.54)
Cranial nerve palsy .08
Yes 0.57
No 1.0
Systemic therapy at diagnosis .01
Yes 3 (1.46 to 7.3)
No 1.0
Category of systemic therapy .14
Cytotoxic chemotherapy 1.0
Targeted chemotherapy 1.03 (0.51 to 2.09)
Both 1.84 (0.99 to 3.41)
Systemic therapy type
Cytotoxic 1.59 (0.73 to 3.45) .24
EGFR inhibitor 2.32 (1.1 to 4.82) .03
HDAC inhibitor 1.49 (0.62 to 3.6) .38
mTOR inhibitor 0.98 (0.11 to 8.66) .98
Bevacizumab 2.67 (1.09 to 6.55) .03
Other targeted agent 0.71 (0.22 to 2.28) .56
Radiologic
Tumor dimension, mm .58
AP —
Transverse 0.99 (0.96 to 1.02)
CC —
Extrapontine extension .91
Yes 0.95 (0.36 to 2.43)
No 1.0
Molecular
H3F3A mutation .04
Yes 1.0
No 1.14 (1.01 to 1.28)
HIST1H3B mutation .002
Yes 1.0
No 0.78 (0.67 to 0.91)
ACVR1 mutation .09
Yes 1
No 0.75 (0.54 to 1.03)
TP53 mutation .36
Yes 1
No 0.92 (0.76 to 1.1)
NOTE. Necrosis, enhancement, and WHO grade were excluded because .
15% of data for these variables were missing. Types of systemic therapy are not
mutually exclusive and were not excluded for multiple therapies.
Abbreviations: AP, anterior-posterior; CC, craniocaudal; EGFR, epidermal
growth factor receptor; HDAC, histone deacetylase; mTOR, mammalian target
of rapamycin.
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Janssens et al29 reported improved OS in 31 children with
DIPG who received reirradiation at first progression (13.7 months)
compared with a matched control cohort (10.3 months) despite
similar PFS (8.2 v 7.7 months, respectively). Progression was not
defined or centrally reviewed in our study; however, we noted that
the proportion of patients with recorded progression within 1 year
of diagnosis was significantly lower among patients who underwent
reirradiation compared with those who did not, suggesting potential
clinician bias to recommend reirradiation to patients with a more
indolent disease course or potentially greater sensitivity to initial RT
in patients who ultimately received reirradiation. As postulated by
others,30 increased RT sensitivity may be a manifestation of distinct
biology. We did not report reirradiation-based outcomes given
limitations conferred by analysis of registry data; more robust
analysis of the effect of reirradiation in patients with DIPG would
be best assessed prospectively in the context of a clinical trial.
On the basis of the radiographic definition of DIPG by
Barkovich et al,31 patients with, 50% pontine involvement (n = 5)
were excluded. Similar to a prior report,5 these patients had better
median OS (20 months), and two patients were LTSs. Greater
craniocaudal tumor dimension and extrapontine extension were
associated with shorter survival; the former finding contrasts with
a report by Poussaint et al,32 in which larger tumor at diagnosis was
associated with longer survival.
As previously described,32 tumor necrosis and ring en-
hancement were associated with short-term survival in univariable
analysis. Multivariable analysis was not performed because. 15%
of data were missing for each variable, precluding comparison of
our findings to the validated multiparametric prediction model
published by Jansen et al.2
DIPG biology has been intensely studied since discovery of
first-in-human histone mutations in 2012.15 Our findings confirm
the independent association of H3.1 K27M and H3.3 K27M with
long- and short-term survival, respectively.3,15 Median OS did not
significantly differ between histone wild-type and mutant DIPGs;
this contrasts with the report by Khuong-Quang et al15 of longer
median OS (4.59 years) for patients with histone wild-type tumors.
In univariable analysis, WHO grade did not differ between
LTSs and STSs (Table 1), but on Kaplan-Meier analysis, WHO
grade 2 was associated with longer survival (Fig 3D). In the most
recent WHO classification of CNS tumors,33 K27M-mutant midline
gliomas are classified asWHOgrade 4 regardless of histology, making
this point less relevant. Tumors classified as primitive neuro-
ectodermal tumors (now called embryonal tumor not otherwise
specified) may represent true embryonal mimics of DIPG or result
from sampling error in the context of intratumoral heterogeneity.
Embryonal pontine tumors often demonstrate sharp margination
and eccentric location, whereas others have radiologic character-
istics indistinguishable from DIPG,34 like those excluded from our
study (Appendix Table A2, online only).
A limitation of this study is use of disease-specific registry data,
which are susceptible to enrollment bias on the part of participating
institutions (which tend to be large academic centers) and patients
or families who self-refer. Variation in standards of care between
countries and institutions may have also influenced findings.
Anonymity of registry data makes some overlap of registry patients
with those previously reported possible, biasing our findings toward
similarity with published literature because they are not completely
independent cohorts. The primary strength of this study is mandated
central review of diagnostic imaging with cross-validation by highly
experienced pediatric neuroradiologists and use of standardized case
report forms. To our knowledge, this study represents the largest,
most comprehensively annotated cohort of radiographically con-
firmed DIPGs reported, offering the most accurate rates of long- and
very long–term survival for this rare tumor. Identification of robust
survival-associated factors in this study is vital for development of
prognostic subgroups and emphasizes patient subsets from whom
the most could be learned from analyzing pretreatment biopsy
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Fig 4. Genomic aberrations in long-term survivors of
diffuse intrinsic pontine glioma (DIPG). DIPG, International
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tissue. Understanding biologic differences that confer survival advantage
in DIPG paves the road toward development of subgroup-specific
therapies that, when implemented in the context of clinical trials,
may improve outcomes for this devastating disease.
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Fig A1. Very long–term survivors of diffuse intrinsic pontine glioma in the current study comparedwith those described in the literature. Yellow highlight indicates atypical
radiologic features that would have been excluded in the current study. Bev, bevacizumab; CN, cranial nerve; DIPG, diffuse intrinsic pontine glioma; EGFR, epidermal
growth factor; GER, Germany, Switzerland, Austria; GOSH, Great Ormond Street Hospital; HDAC, histone deacetylase inhibitor; HGG, high-grade glioma; IDIPGR, In-
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Fig A2. (A) Comparison of characteristics of patients who received therapy or did
not receive therapy at diagnosis. (B) Magnetic resonance images and clinical
characteristics of two long-term survivors (LTSs) of diffuse intrinsic pontine glioma
who did not receive therapy. CN, cranial nerve; GER, Germany, Switzerland,
Austria; LFU, last follow-up; NETH, the Netherlands; OS, overall survival; Re-RT,
reirradiation; RT, radiation therapy.
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Fig A3. Clinical, radiologic, and molecular characteristics of patients with diffuse
intrinsic pontine glioma age. 18 years. Bev, bevacizumab; CN, cranial nerve; DIPG,
International DIPG Registry; EGFR, epidermal growth factor; FR, France; GER,
Germany, Switzerland, Austria; HDAC, histone deacetylase inhibitor; IT, Italy; LFU,
last follow-up; OS, overall survival; Re-RT, reirradiation; RT, radiation therapy; WT,
wild type.
Table A1. Biopsies and Autopsies Performed by Country or Region
Country
No./Total No. (%)
Biopsy Autopsy
SIOPE-DIPGR
France 109/113 (96) 2/115 (2)
Germany/Switzerland/Austria 81/278 (29) 4/16 (25)
The Netherlands 29/114 (25) 10/113 (9)
Italy 17/79 (22) 0/71 (0)
Croatia 2/7 (29) 0/5 (0)
United Kingdom 7/43 (16) 0/43 (0)
IDIPGR
United States/Canada/Australia 54/372 (15) 61/376 (16)
Abbreviations: IDIPGR: International Diffuse Intrinsic Pontine Glioma Registry;
SIOPE-DIPGR, European Society for Pediatric Oncology Diffuse Intrinsic Pontine
Glioma Registry.
jco.org © 2018 by American Society of Clinical Oncology
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Table A2. Clinical, Radiologic, and Molecular Characteristics of Patients With Primitive Neuroectodermal Tumor
Patient Age (months)
Symptom
Duration (weeks) Symptoms Treatment at Diagnosis OS (months) Source of Tissue Molecular Findings
DIPG-0051 27 Unknown Unknown RT + vorinostat 6 Biopsy WT H3.3
DIPG-0165 53 , 6 CN, pyramidal RT + vorinostat 7 Biopsy WT PDGFRA and EGFR
DIPG-0236 62 , 6 Unknown RT 5 Autopsy Mutant TP53 and NF1
Amplified MYCN
WT H3.3, H3.1, ACVR1,
PDGFRA, EGFR, ATRX,
DAXX, PIK3CA, MET,
CDKN2A/B, CCND1/2,
CDK6, PPM1D
Abbreviations: CN, cranial nerve; DIPG, International DIPG Registry; OS, overall survival; RT, radiation therapy; WT, wild type.
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